Book a Meeting

Non-Fucosylated Anti-Human TRAIL Receptor-1 (4H6.17.8) Therapeutic Antibody (CAT#: BioBet-1376ZP) Datasheet

Target
TRAIL Receptor-1
Isotype
IgG
Description
ADCC-Enhanced anti-TRAIL Receptor-1 (4H6.17.8) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Indication
Cancer
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced TRAIL Receptor-1 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
TNFRSF10A
Full Name
tumor necrosis factor receptor superfamily, member 10a
Background
The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL), and thus transduces cell death signal and induces cell apoptosis. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein.
Alternative Names
TNFRSF10A; tumor necrosis factor receptor superfamily, member 10a; DR4; APO2; CD261; TRAILR1; TRAILR-1; tumor necrosis factor receptor superfamily member 10A; TRAIL-R1; TRAIL receptor 1; death receptor 4; cytotoxic TRAIL receptor; TNF-related apoptosis-inducing ligand receptor 1; tumor necrosis factor receptor superfamily member 10a variant 2
Gene ID
8797
Cellular Localization
Plasma membrane, Cytosol
Involvement in Disease
Diseases associated with TNFRSF10A include Hirata Disease and Temporal Arteritis.
Related Pathways
Its related pathways are Apoptosis Modulation and Signaling and Signaling by GPCR.
Function
The cytotoxic ligand TNFSF10/TRAIL receptor. The adaptor molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signal complex (DISC) performs proteolytic activation of caspase-8, which in turn initiates a cascade of caspase (aspartate-specific cysteine protease) and mediates apoptosis. Promote the activation of nf-kpa-b.
Field of research
Cell Biology and Cellular Response antibody; Cell Death antibody; Immune System antibody
Post-translational modifications
1.Palmitoylated (PubMed:19090789). Palmitoylation of TNFRSF10A is required for its association with lipid rafts, oligomerization and function in TRAIL-induced cell death (PubMed:19090789). Palmitoylated by ZDHHC3 (Probable) 2.Modification sites at PhosphoSitePlus 3.Glycosylation at Asn156
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
4H6.17.8
Host
Humanized
Species Reactivity
Human
Description
The DR4 antibody which are capable of specifically binding to DR4 are useful in the treatment of various diseases and pathological conditions, including cancer.
Indication
Cancer

Cancer

Related Products

Non-Fucosylated Anti-Human TRAIL Receptor-1 (4E7.24.3) Therapeutic Antibody (CAT#: BioBet-1375ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.